The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: An Anocef phase II trial.
German Reyes-Botero
No relevant relationships to disclose
Jerôme Honnorat
Honoraria - Roche/Genentech
Expert Testimony - Roche/Genentech
Other Remuneration - Roche/Genentech
Oliver L. Chinot
Consultant or Advisory Role - Roche
Honoraria - AstraZeneca; MSD; Roche
Research Funding - Merck; Roche
Luc Taillandier
No relevant relationships to disclose
Isabelle Catry-Thomas
No relevant relationships to disclose
Jerome Barriere
No relevant relationships to disclose
Jean Sebastien Guillamo
No relevant relationships to disclose
Michel Fabbro
No relevant relationships to disclose
Didier Frappaz
No relevant relationships to disclose
Alexandra Benouaich Amiel
Research Funding - Roche
Other Remuneration - Roche
Emilie Le Rhun
No relevant relationships to disclose
Chantal Campello
No relevant relationships to disclose
Isabelle Tennevet
No relevant relationships to disclose
François Ghiringhelli
No relevant relationships to disclose
Marie-Laure Tanguy
No relevant relationships to disclose
Karima Mokhtari
No relevant relationships to disclose
Jean-Yves Delattre
No relevant relationships to disclose